271 related articles for article (PubMed ID: 28607026)
1. Efficacy of Paromomycin-Chloroquine Combination Therapy in Experimental Cutaneous Leishmaniasis.
Wijnant GJ; Van Bocxlaer K; Yardley V; Murdan S; Croft SL
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607026
[TBL] [Abstract][Full Text] [Related]
2. Combined topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) major leads to reduction in both lesion size and systemic parasite burdens.
Aguiar MG; Silva DL; Nunan FA; Nunan EA; Fernandes AP; Ferreira LA
J Antimicrob Chemother; 2009 Dec; 64(6):1234-40. PubMed ID: 19825819
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Apigenin and Miltefosine Combination Therapy against Experimental Cutaneous Leishmaniasis.
Emiliano YSS; Almeida-Amaral EE
J Nat Prod; 2018 Aug; 81(8):1910-1913. PubMed ID: 30095915
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous leishmaniasis treatment.
Minodier P; Parola P
Travel Med Infect Dis; 2007 May; 5(3):150-8. PubMed ID: 17448941
[TBL] [Abstract][Full Text] [Related]
5. Combination of paromomycin plus human anti-TNF-α antibodies to control the local inflammatory response in BALB/ mice with cutaneous leishmaniasis lesions.
Schwartz J; Moreno E; Calvo A; Blanco L; Fernández-Rubio C; Sanmartín C; Nguewa P; Irache JM; Larrea E; Espuelas S
J Dermatol Sci; 2018 Oct; 92(1):78-88. PubMed ID: 30037731
[TBL] [Abstract][Full Text] [Related]
6. Amphotericin B resistance in Leishmania amazonensis: In vitro and in vivo characterization of a Brazilian clinical isolate.
Ferreira BA; Coser EM; de la Roca S; Aoki JI; Branco N; Soares GHC; Lima MIS; Coelho AC
PLoS Negl Trop Dis; 2024 May; 18(5):e0012175. PubMed ID: 38768213
[TBL] [Abstract][Full Text] [Related]
7. In vivo activity of perifosine against Leishmania amazonensis.
Cabrera-Serra MG; Valladares B; Piñero JE
Acta Trop; 2008 Oct; 108(1):20-5. PubMed ID: 18801328
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of a Binuclear Cyclopalladated Compound Therapy for Cutaneous Leishmaniasis in the Murine Model of Infection with Leishmania amazonensis and Its Inhibitory Effect on Topoisomerase 1B.
Velásquez AMA; Ribeiro WC; Venn V; Castelli S; Camargo MS; de Assis RP; de Souza RA; Ribeiro AR; Passalacqua TG; da Rosa JA; Baviera AM; Mauro AE; Desideri A; Almeida-Amaral EE; Graminha MAS
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28507113
[TBL] [Abstract][Full Text] [Related]
9. Colloidal, in vitro and in vivo anti-leishmanial properties of transfersomes containing paromomycin sulfate in susceptible BALB/c mice.
Bavarsad N; Fazly Bazzaz BS; Khamesipour A; Jaafari MR
Acta Trop; 2012 Oct; 124(1):33-41. PubMed ID: 22750480
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the in vitro and in vivo antileishmanial activity of a chloroquinolin derivative against Leishmania species capable of causing tegumentary and visceral leishmaniasis.
Soyer TG; Mendonça DVC; Tavares GSV; Lage DP; Dias DS; Ribeiro PAF; Perin L; Ludolf F; Coelho VTS; Ferreira ACG; Neves PHAS; Matos GF; Chávez-Fumagalli MA; Coimbra ES; Pereira GR; Coelho EAF; Antinarelli LMR
Exp Parasitol; 2019 Apr; 199():30-37. PubMed ID: 30817917
[TBL] [Abstract][Full Text] [Related]
11. Reductions in skin and systemic parasite burdens as a combined effect of topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) amazonensis.
Aguiar MG; Pereira AM; Fernandes AP; Ferreira LA
Antimicrob Agents Chemother; 2010 Nov; 54(11):4699-704. PubMed ID: 20713665
[TBL] [Abstract][Full Text] [Related]
12. Direct comparison of the efficacy and safety of oral treatments with oleylphosphocholine (OlPC) and miltefosine in a mouse model of L. major cutaneous leishmaniasis.
Fortin A; Caridha DP; Leed S; Ngundam F; Sena J; Bosschaerts T; Parriott S; Hickman MR; Hudson TH; Grogl M
PLoS Negl Trop Dis; 2014 Sep; 8(9):e3144. PubMed ID: 25210745
[TBL] [Abstract][Full Text] [Related]
13. Appraisal of a Leishmania major strain stably expressing mCherry fluorescent protein for both in vitro and in vivo studies of potential drugs and vaccine against cutaneous leishmaniasis.
Calvo-Álvarez E; Guerrero NA; Alvarez-Velilla R; Prada CF; Requena JM; Punzón C; Llamas MÁ; Arévalo FJ; Rivas L; Fresno M; Pérez-Pertejo Y; Balaña-Fouce R; Reguera RM
PLoS Negl Trop Dis; 2012; 6(11):e1927. PubMed ID: 23209866
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of lapachol on treatment of cutaneous and visceral leishmaniasis.
Araújo IAC; de Paula RC; Alves CL; Faria KF; Oliveira MM; Mendes GG; Dias EMFA; Ribeiro RR; Oliveira AB; Silva SMD
Exp Parasitol; 2019 Apr; 199():67-73. PubMed ID: 30797783
[TBL] [Abstract][Full Text] [Related]
15. Topical treatment with hexadecylphosphocholine (Miltex) efficiently reduces parasite burden in experimental cutaneous leishmaniasis.
Schmidt-Ott R; Klenner T; Overath P; Aebischer T
Trans R Soc Trop Med Hyg; 1999; 93(1):85-90. PubMed ID: 10492799
[TBL] [Abstract][Full Text] [Related]
16. Comparison of
Özbilgin A; Çavuş İ; Kaya T; Yıldırım A; Harman M
Turkiye Parazitol Derg; 2020 Mar; 44(1):12-16. PubMed ID: 32212583
[TBL] [Abstract][Full Text] [Related]
17. Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (Aminosidine) and gentamicin.
Grogl M; Schuster BG; Ellis WY; Berman JD
J Parasitol; 1999 Apr; 85(2):354-9. PubMed ID: 10219319
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of oleylphosphocholine in experimental cutaneous leishmaniasis.
Van Bocxlaer K; Dixon J; Platteeuw JJ; Van Den Heuvel D; Mcarthur KN; Harris A; Alavijeh M; Croft SL; Yardley V
J Antimicrob Chemother; 2023 Jul; 78(7):1723-1731. PubMed ID: 37229566
[TBL] [Abstract][Full Text] [Related]
19. In Vitro and In Vivo Antileishmanial Activity of Thioridazine.
Sifontes-Rodríguez S; Mollineda-Diogo N; Monzote-Fidalgo L; Escalona-Montaño AR; Escario García-Trevijano JA; Aguirre-García MM; Meneses-Marcel A
Acta Parasitol; 2024 Mar; 69(1):324-331. PubMed ID: 38070122
[TBL] [Abstract][Full Text] [Related]
20. Leishmania major: in vitro and in vivo anti-leishmanial activity of paromomycin ointment (Leshcutan) combined with the immunomodulator Imiquimod.
El-On J; Bazarsky E; Sneir R
Exp Parasitol; 2007 Jun; 116(2):156-62. PubMed ID: 17306255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
